Figure 1.

Clinical impact of EML4-ALK fusion variant V3. Differences in clinical course and patient outcome with various therapeutic modalities of lung adenocarcinoma driven by EML4-ALK V3 vs. V1/V2. The collective insight from several recent publications (8-12) is visualized, with arrow lengths roughly proportional to the corresponding progression-free and overall survival intervals as estimated by considering the different published series together. However, there is substantial heterogeneity, which probably reflects additional effects from further important biological factors that remain to be determined. Numbers in parentheses indicate references of the article; EML4, echinoderm microtubule-associated protein-like 4; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; EMT, epithelial-mesenchymal transition.